Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers

• Status: Unknown status
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether irbesartan will reduce the rate of recurrent atrial high rate episodes and the development of clinical sustained atrial fibrillation in patients with hypertension and permanent pacemaker.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Connolly, Stuart, M.D.
• Collaborators: Bristol-Myers Squibb; Sanofi
• Treatments: Irbesartan

Criteria

Inclusion Criteria:

• Sinus Node Dysfunction (with or without AV conduction disturbance)

• Permanent, atrial or dual-chamber pacemaker implanted > 2 months before enrollment and with ability to record and store atrial high-rate episodes, frequency of mode switches and to perform non-invasive electrophysiologic testing

• History of at least 6 AHRE in the last 6 months (rate > 220/min, duration of > 2 minutes

• History of prior diagnosis of hypertension and/or treated for hypertension OR two documented BP > 130/85 (measurements done at least one week apart)

Exclusion Criteria:

• Permanent or persistent AF or more than 6 episodes of symptomatic paroxysmal AF in the previous 6 months

• Documented Cr >200 umol/L and K+ >5.2 mmol/L in the previous 3 months

• Current treatment with a potassium sparing diuretic, unless serum potassium known to be in the normal range

• LV ejection fraction known to be < 40 %

• Moderate or severe mitral regurgitation (3+, 4 +)

• Mitral stenosis of more than mild severity

• Aortic stenosis with mean gradient of > 25 mmHg

• Angina at rest in the last 2 months, or current CCS Class 3 or 4 angina

• Unipolar atrial lead

• Previous AV node ablation

• P-wave amplitude less than 1.5 mV

• Current therapy with an ACE inhibitor, ARB or aldosterone antagonist

• Current or planned (within 6 months) with an anti-arrhythmic medication (amiodarone, sotalol, flecainide, propafenone, quinidine, dofetilide